Monopar Therapeutics (MNPR) Profit After Tax (2017 - 2020)
Monopar Therapeutics (MNPR) has disclosed Profit After Tax for 4 consecutive years, with -$2.1 million as the latest value for Q4 2020.
- Quarterly Profit After Tax fell 76.36% to -$2.1 million in Q4 2020 from the year-ago period, while the trailing twelve-month figure was -$6.3 million through Dec 2020, down 49.23% year-over-year, with the annual reading at -$15.6 million for FY2024, 85.94% down from the prior year.
- Profit After Tax hit -$2.1 million in Q4 2020 for Monopar Therapeutics, down from -$1.6 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of -$372915.0 in Q1 2017 to a low of -$14.9 million in Q3 2017.
- Historically, Profit After Tax has averaged -$1.9 million across 4 years, with a median of -$898080.5 in 2018.
- Biggest YoY gain for Profit After Tax was 95.7% in 2018; the steepest drop was 135.0% in 2018.
- Year by year, Profit After Tax stood at -$713583.0 in 2017, then dropped by 24.79% to -$890461.0 in 2018, then crashed by 35.53% to -$1.2 million in 2019, then tumbled by 76.36% to -$2.1 million in 2020.
- Business Quant data shows Profit After Tax for MNPR at -$2.1 million in Q4 2020, -$1.6 million in Q3 2020, and -$1.4 million in Q2 2020.